|
Patent landscape, scope, and claims summary: |
Comprehensive Patent Landscape Analysis for US Patent 10,132,813: SLE Risk Scoring Using EC4d, BC4d, and Anti-MCV, Plus Logistic Regression and Treatment Selection
US 10,132,813 is directed to a United States method claim for identifying and treating a human subject for systemic lupus erythematosus (SLE) using a marker panel (erythrocyte C4d, B-cell C4d, and anti-MCV antibody) and a calculated SLE risk score produced using logistic regression with marker weighting, where the subject is then treated with specified SLE therapeutics. The core patentability and enforcement leverage sits in (1) the exact combination of EC4d, BC4d, and anti-MCV into a risk score, (2) the explicit risk-threshold logic using comparative standards (SLE vs non-SLE autoimmune populations), and (3) logistic regression weighting/transformations that generate the risk score. The breadth of the claim is also its vulnerability: it covers broad sample architectures (samples may be same or different), broad transformation/weighting concept (logistic regression with coefficients), and broadly defined treatment options, which can be easier to design around at the assay and algorithm levels.
What is US Patent 10,132,813 claiming for SLE diagnosis and treatment using EC4d, BC4d, anti-MCV, and logistic regression?
Answer: The claims recite a method that measures three immunologic markers (EC4d, BC4d, anti-MCV), converts/weights them through logistic regression (transform analyses with coefficients per marker), compares the resulting SLE risk score to predetermined population-derived standards (SLE and/or non-SLE autoimmune), classifies the subject as likely to have SLE based on that comparison, and then treats with one or more listed SLE therapeutics.
Claim 1: Marker panel plus algorithmic risk classification plus treatment selection
Claim 1 requires steps (paraphrased into patent elements):
- Identify a human subject “negative for SLE” based on anti-dsDNA marker levels.
- Measure markers from blood samples:
- EC4d in a first blood sample (erythrocyte C4d on erythrocytes)
- BC4d in a second blood sample (B-cell C4d on B lymphocytes)
- anti-MCV antibody in a third blood sample
- Samples can be the same or different.
- Calculate an “SLE risk score” by transforming marker levels and using logistic regression:
- Apply one or more transformation analyses (explicitly includes logistic regression).
- Logistic regression includes:
- adjusting marker levels by an “appropriate weighting coefficient” to produce a weighted score per marker
- combining weighted scores to generate the risk score
- Compare the risk score to one or more predetermined standards:
- a predetermined risk score derived from a population with SLE
- and/or a predetermined risk score derived from a population with non-SLE autoimmune disease
- Classify the subject as likely to have SLE if:
- the risk score is increased compared to the non-SLE autoimmune standard, or
- equivalent to the SLE population standard
- Treat the subject likely to have SLE with an amount effective using one or more therapeutics from a specified list:
- cyclophosphamide, corticosteroids, mycophenolate, methotrextate, azathioprine, leflunomide, belimumab, plaquenil (hydroxychloroquine)
Dependent claims 2-6: tightening and implementation specifics
- Claim 2 adds ANA measurement in the third sample, and adds ANA into the logistic regression risk-score transformations.
- Claim 3 specifies phenotypic determination:
- BC4d measured on B lymphocytes
- EC4d measured on erythrocytes
- Claim 4 specifies sample types:
- second blood sample can be a cell/tissue extract comprising B lymphocytes
- first blood sample can be a cell/tissue extract comprising erythrocytes
- Claim 5 specifies assay format:
- determination of BC4d and EC4d using an antibody specific for C4d
- Claim 6 narrows sample roles: first sample is erythrocyte-containing extract; second sample is B-lymphocyte-containing extract.
Which technical features in claim 1 are most likely to drive validity and infringement?
Answer: The most legally consequential features are the three-marker combination (EC4d + BC4d + anti-MCV), the explicit requirement that risk is calculated via logistic regression with marker-specific weighting coefficients, and the classification step using population-derived SLE vs non-SLE autoimmune risk-score standards, followed by treatment.
High-leverage claim elements for enforcement
- Triple marker panel
- EC4d and BC4d are both complement-C4d-related, but on distinct cell compartments (erythrocytes vs B lymphocytes).
- anti-MCV introduces a separate antibody axis.
- A design-around that omits any one marker is the cleanest route to avoid literal infringement.
- Logistic regression architecture
- Claim 1 does not merely require “a model” or “a scoring algorithm.”
- It explicitly requires logistic regression and describes weighting coefficients per marker.
- Comparison to predetermined population standards
- Many diagnostic claims become vulnerable when they are functional or vague about thresholds.
- Here, the claim anchors classification to “pre-determined SLE risk score derived from a population,” and also provides an alternative anchor to non-SLE autoimmune population.
- Treatment step
- The claim is a treatment method tied to the classification.
- This adds an enforcement hook where a workflow is captured end-to-end (test, classify, treat).
Vulnerability points that can narrow practical scope
- “Anti-dsDNA negative” inclusion condition
- The method is defined for subjects identified as “negative for SLE based on double stranded DNA antibody marker levels.”
- If a competitor’s clinical workflow does not restrict to dsDNA-negative patients at the time of testing, they may be able to argue no coverage.
- “Equivalent to” SLE risk score standard
- “Equivalent” can be litigated on how thresholds and equality are operationalized in practice.
- If a competitor uses strict cutoffs rather than equivalence bands, there can be non-infringement arguments.
- Transformations are broad but are constrained by logistic regression
- Claim 1 allows “one or more transformation analyses” but then defines logistic regression structure.
- Competitors that use non-logistic-regression models (or logistic regression without the described weighting-and-combining structure) can aim for design-around.
How does US 10,132,813 compare to other SLE diagnostic approaches using complement C4d and autoantibodies?
Answer: US 10,132,813 is positioned as an SLE risk stratification method that leverages compartment-specific C4d (EC4d and BC4d) plus anti-MCV, and ties classification to logistic-regression scoring against population standards. Compared with single-biomarker or anti-dsDNA-only approaches, it is more algorithmic and multi-dimensional.
Competitive technical design space the claim targets
- Current diagnostic gating often relies heavily on clinical criteria and serologies such as anti-dsDNA and complement levels (C3/C4), with anti-dsDNA negativity not excluding eventual SLE.
- This patent’s novelty posture (based on claim structure, not prosecution history) is the combination of:
- C4d detection on specific cellular targets (erythrocytes and B lymphocytes)
- and anti-MCV antibody
- combined in a logistic regression risk framework.
Likely “close” alternatives that reduce infringement risk
- Using C4d only (without anti-MCV), or anti-MCV only, is the most direct carve-out.
- Using other ML models (e.g., random forest, neural net) instead of logistic regression is a key avoidance lever.
- Using logistic regression but with a scoring method that does not follow the claim’s described weighting-and-combining structure (as implemented and documented) is another pathway, though the scope of “comprising logistic regression” can be litigated broadly.
What is the strongest and weakest aspect of the claim’s breadth for licensing and litigation?
Answer: Strongest aspects are the specific marker panel plus logistic regression and population-based risk thresholds. Weakest aspects are broad sample permissiveness and broad treatment selection, which can increase non-infringement and validity attack surface through prior art and design-around.
Strongest for licensing
- A licensing proposition is strongest when:
- the target product or clinical assay workflow uses EC4d and BC4d plus anti-MCV, and
- outputs an SLE risk score computed by logistic regression with per-marker weighting, and
- uses an SLE vs non-SLE standard threshold derived from populations.
- The treatment step can broaden enforcement leverage when the assay is used as part of a care pathway.
Weakest for absolute coverage
- Treatment list breadth can create redundancy with standard-of-care; if prior art discloses treating based on SLE classification generally, the novelty may be challenged.
- The claim permits “samples may be the same or different,” which can be attacked as not limiting to a particular assay workflow. Competitors can change sample handling without changing marker content, potentially still falling within claim language but making infringement factual.
- Broad transformation allowance (“one or more transformation analyses”) can be attacked for indefiniteness or for overbreadth if prior art shows similar regression scoring with transformed variables.
How many patent claims and dependent claim variations exist in the independent claim set?
Answer: Based on the text provided, claim 1 is the independent claim and claims 2-6 are dependent variants. Within this limited excerpt, the claim set covers:
- additional ANA inclusion (claim 2)
- explicit cell-type localization for BC4d/EC4d (claims 3 and 6)
- sample extract/cell fraction workflows (claim 4)
- antibody-specific C4d detection (claim 5)
Practically, the patent estate is built to capture both assay technology choices and the risk model inputs, with dependent claims adding implementation constraints that can become fallback positions in claim construction.
What design-around strategies are most likely to avoid literal infringement of US 10,132,813?
Answer: The cleanest routes are to change at least one of the claim’s hard constraints: marker panel membership, logistic regression requirement, or the population-threshold comparison logic.
High-probability design-arounds
- Remove anti-MCV from the panel
- Claim 1 requires anti-MCV marker in a third blood sample.
- Remove either EC4d or BC4d
- Either omission breaks the literal marker combination.
- Use a non-logistic-regression scoring model
- Claim requires logistic regression analysis with weighting coefficients producing a risk score.
- Use risk classification not based on pre-determined population-derived SLE/non-SLE standards
- If the threshold is not derived from population SLE vs non-SLE autoimmune distributions, classification may fall outside literal requirements.
- Do not apply the method to “anti-dsDNA negative” subjects
- If a workflow applies to all-comers or includes dsDNA-positive patients in the decision, the “identified as negative” gate may become a litigation issue.
Lower-probability design-arounds (fact intensive)
- Switching assay modality while still using C4d-specific antibodies (claim 5) may or may not avoid infringement because claim 1 only needs levels, not antibody format.
- Changing sample ordering or using composite extraction could still land within “samples may be the same or different.”
How could patent strength be assessed for US 10,132,813 based on claim structure?
Answer: The claim is likely to face validity scrutiny around:
- whether prior art disclosed EC4d/BC4d measurement on defined cell types for SLE and/or autoimmune differential diagnosis,
- whether prior art disclosed anti-MCV usage in SLE or related conditions,
- whether prior art disclosed combining multiple biomarkers into a logistic-regression SLE risk score with population-derived thresholds.
Claim-structure-driven prior art exposure
- Multi-marker diagnostic models are common in immunology diagnostics.
- Logistic regression is a classic statistical classifier.
- The specific novelty, if it exists, is the combination of EC4d/BC4d with anti-MCV and the dsDNA-negative gate plus SLE vs non-SLE population thresholding.
From a litigation posture perspective, those novelty hinges dictate that the strongest infringement cases will involve evidence that the accused assay includes the same marker triad and uses logistic regression with population-derived thresholds as described.
What does the claim imply about FDA status and regulatory framing for any assay using this IP?
Answer: The patent is written as a method of diagnosing and treating SLE, which aligns with an in vitro diagnostic (IVD) or algorithmic clinical decision support workflow. However, the patent itself does not define an FDA regulatory pathway. In practice, any company commercializing a risk score based on these markers would need to validate analytic performance (assay) and clinical validity (outcomes/thresholds).
No Orange Book status analysis can be generated from the excerpt alone because the patent number alone does not specify whether it is listed for a particular FDA-approved drug in the Orange Book.
What commercial and competitive scenarios are most exposed to US 10,132,813?
Answer: The most exposed scenarios are those where a commercial IVD test or clinical algorithm measures EC4d, BC4d, and anti-MCV, computes an SLE risk score using logistic regression weighting, and then results in a clinician treating the patient using SLE therapeutics.
Exposure map by workflow step
- Testing step (EC4d/BC4d/anti-MCV quantification): high exposure if all markers are used.
- Algorithm step (logistic regression risk score): high exposure if logistic regression with coefficients is used.
- Decision thresholding step (population-derived SLE vs non-SLE standards): high exposure if thresholds are population-defined and stored as predetermined cutoffs.
- Treatment step: high exposure if the claim is asserted against a pathway that explicitly uses the risk classification to select SLE therapy.
Key Takeaways
- US 10,132,813 claims an end-to-end SLE risk identification and treatment method centered on EC4d + BC4d + anti-MCV measured from blood-derived samples, and an SLE risk score generated by logistic regression with marker weighting coefficients.
- The classification step uses predetermined population-derived SLE and/or non-SLE autoimmune risk-score standards, and treatment selection uses a defined list including belimumab and hydroxychloroquine among others.
- The strongest enforcement leverage is the specific triad of markers plus logistic regression scoring plus population-derived risk threshold comparison.
- The highest-probability design-arounds are omission of a required marker (anti-MCV, EC4d, or BC4d), use of a non-logistic regression scoring method, and avoiding the population-standard thresholding framework or the dsDNA-negative gating.
FAQs
- Can a clinician use a similar biomarker panel for SLE without infringing if the risk score uses a neural network instead of logistic regression?
- If a diagnostic workflow includes EC4d and BC4d but replaces anti-MCV with a different antibody, does claim 1 still get triggered?
- Does the “equivalent to the predetermined SLE risk score” language create room for strict-threshold implementations to avoid literal infringement?
- How does measuring BC4d/EC4d with non-antibody detection methods affect coverage under claim 5?
- If clinicians treat SLE without using the patented risk score as an explicit decision gate, can the treatment step be argued away?
References
- United States Patent 10,132,813, claims excerpt provided in the prompt.
More… ↓
⤷ Start Trial
|
